DK1682583T3 - Proteinkompleksdannelse under anvendelse af immunoglobulinfragment samt fremgangsmåde til fremstilling deraf - Google Patents
Proteinkompleksdannelse under anvendelse af immunoglobulinfragment samt fremgangsmåde til fremstilling derafInfo
- Publication number
- DK1682583T3 DK1682583T3 DK04800091.3T DK04800091T DK1682583T3 DK 1682583 T3 DK1682583 T3 DK 1682583T3 DK 04800091 T DK04800091 T DK 04800091T DK 1682583 T3 DK1682583 T3 DK 1682583T3
- Authority
- DK
- Denmark
- Prior art keywords
- fragment
- igg
- preparation
- drug
- protein complex
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 title 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 title 1
- 230000009918 complex formation Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 abstract 4
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 238000001727 in vivo Methods 0.000 abstract 2
- 238000012258 culturing Methods 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Inorganic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20030080299 | 2003-11-13 | ||
PCT/KR2004/002944 WO2005047336A1 (en) | 2003-11-13 | 2004-11-13 | Protein complex using immunoglobulin fragment andmethod for the preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1682583T3 true DK1682583T3 (da) | 2012-05-07 |
Family
ID=36589418
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10009129.7T DK2256134T3 (da) | 2003-11-13 | 2004-11-13 | IgG Fc-fragment til en lægemiddelbærer og fremgangsmåde til fremstilling deraf |
DK04800091.3T DK1682583T3 (da) | 2003-11-13 | 2004-11-13 | Proteinkompleksdannelse under anvendelse af immunoglobulinfragment samt fremgangsmåde til fremstilling deraf |
DK10006326.2T DK2239273T3 (da) | 2003-11-13 | 2004-11-13 | Farmaceutisk sammensætning, der omfatter en immunoglobulin Fc-region som en bærer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10009129.7T DK2256134T3 (da) | 2003-11-13 | 2004-11-13 | IgG Fc-fragment til en lægemiddelbærer og fremgangsmåde til fremstilling deraf |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10006326.2T DK2239273T3 (da) | 2003-11-13 | 2004-11-13 | Farmaceutisk sammensætning, der omfatter en immunoglobulin Fc-region som en bærer |
Country Status (17)
Country | Link |
---|---|
US (13) | US8029789B2 (da) |
EP (6) | EP1682582B1 (da) |
JP (7) | JP2007531513A (da) |
KR (5) | KR100775343B1 (da) |
CN (4) | CN103212084B (da) |
AT (3) | ATE522548T1 (da) |
AU (2) | AU2004282984B2 (da) |
BR (2) | BRPI0406606A (da) |
CA (2) | CA2512933C (da) |
DK (3) | DK2256134T3 (da) |
ES (6) | ES2438098T3 (da) |
HK (2) | HK1149570A1 (da) |
MX (2) | MXPA05007211A (da) |
PL (2) | PL2256134T3 (da) |
PT (3) | PT2256134E (da) |
RU (2) | RU2356909C2 (da) |
WO (4) | WO2005047334A1 (da) |
Families Citing this family (262)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7157555B1 (en) * | 1997-08-08 | 2007-01-02 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
RS52815B (sr) | 2002-12-20 | 2013-10-31 | Amgen Inc. | Vezivna sredstva koja inhibiraju miostatin |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
PL1624891T5 (pl) | 2003-05-06 | 2014-02-28 | Bioverativ Therapeutics Inc | Białka chimeryczne o strukturze czynnik krzepliwości krwi-fc do leczenia hemofilii |
US7850970B2 (en) | 2003-08-26 | 2010-12-14 | The Regents Of The University Of Colorado | Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
US8110665B2 (en) * | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
EP1682582B1 (en) | 2003-11-13 | 2011-08-31 | Hanmi Holdings Co., Ltd | Method for the mass production of immunoglobulin constant region |
KR101135244B1 (ko) * | 2007-11-29 | 2012-04-24 | 한미사이언스 주식회사 | 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물 |
US8263084B2 (en) * | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
HUE039448T2 (hu) | 2004-04-21 | 2018-12-28 | Alexion Pharma Inc | Csontba szállító konjugátumok és alkalmazási módszerük a fehérjék csontba juttatására |
US20070081984A1 (en) | 2005-10-11 | 2007-04-12 | Shunji Tomatsu | Compositions and methods for treating hypophosphatasia |
EP1773400A2 (en) * | 2004-07-08 | 2007-04-18 | Amgen Inc. | Therapeutic peptides |
KR100594607B1 (ko) * | 2004-11-03 | 2006-06-30 | 재단법인서울대학교산학협력재단 | 신규한 경구투여용 재조합 인간 성장호르몬 분비미생물제제 및 그 제조방법 |
CA2592015A1 (en) * | 2004-12-27 | 2006-07-06 | Progenics Pharmaceuticals (Nevada), Inc. | Orally deliverable and anti-toxin antibodies and methods for making and using them |
CA2597346A1 (en) * | 2005-02-14 | 2006-08-17 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물 |
US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
ES2539250T3 (es) | 2005-07-25 | 2015-06-29 | Emergent Product Development Seattle, Llc | Reducción de células B mediante el uso de moléculas de unión específica a CD37 y de unión específica a CD20 |
US8008453B2 (en) * | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
US7968316B2 (en) * | 2005-08-16 | 2011-06-28 | Hanmi Holdings Co., Ltd. | Method for the mass production of immunoglobulin Fc region deleted initial methionine residues |
KR100824505B1 (ko) * | 2005-08-16 | 2008-04-22 | 한미약품 주식회사 | 개시 메티오닌 잔기가 제거된 면역글로불린 Fc 영역의대량 생산방법 |
CN101534865A (zh) * | 2005-10-19 | 2009-09-16 | Ibc药品公司 | 生物活性装配体的制备方法及其用途 |
US20070122408A1 (en) * | 2005-10-20 | 2007-05-31 | The Scripps Research Institute | Fc Labeling for Immunostaining and Immunotargeting |
TW200732350A (en) * | 2005-10-21 | 2007-09-01 | Amgen Inc | Methods for generating monovalent IgG |
US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
SG10201600950TA (en) * | 2005-11-28 | 2016-03-30 | Genmab As | Recombinant monovalent antibodies and methods for production thereof |
JP2009518422A (ja) * | 2005-12-06 | 2009-05-07 | アムジェン インコーポレイテッド | ミオスタチン・アンタゴニストの使用 |
CN100475270C (zh) | 2006-01-20 | 2009-04-08 | 清华大学 | 一种治疗肿瘤的药物及其应用 |
CN101002945B (zh) | 2006-01-20 | 2012-09-05 | 清华大学 | 一种用于肿瘤治疗的新型复合物 |
CA3149553C (en) * | 2006-06-12 | 2023-11-21 | Aptevo Research And Development Llc | Single-chain multivalent binding proteins with effector function |
LT2061803T (lt) * | 2006-08-28 | 2019-11-25 | Ares Trading Sa | Fc turinčių baltymų gryninimo būdas |
US20140147441A1 (en) * | 2006-09-12 | 2014-05-29 | The General Hospital Corporation | Compositions containing alpha-1-antitrypsin and methods for use |
PE20081140A1 (es) | 2006-10-25 | 2008-09-22 | Amgen Inc | Agentes terapeuticos a base de peptidos derivados de toxinas |
US20080181903A1 (en) * | 2006-12-21 | 2008-07-31 | Pdl Biopharma, Inc. | Conjugate of natriuretic peptide and antibody constant region |
JP2008169195A (ja) * | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
CN101219219B (zh) | 2007-01-10 | 2013-02-13 | 北京普罗吉生物科技发展有限公司 | 包含血管抑素或其片段的复合物、其制备方法及应用 |
US20080238882A1 (en) * | 2007-02-21 | 2008-10-02 | Ramesh Sivarajan | Symmetric touch screen system with carbon nanotube-based transparent conductive electrode pairs |
US8501678B2 (en) | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
TW201718635A (zh) | 2007-03-06 | 2017-06-01 | 安美基公司 | 變異之活動素受體多肽及其用途 |
AU2008262490B2 (en) | 2007-05-22 | 2011-11-17 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
US7867491B2 (en) * | 2007-05-30 | 2011-01-11 | Genexine Co., Ltd. | Immunoglobulin fusion proteins |
US9322035B2 (en) | 2007-05-31 | 2016-04-26 | Genmab A/S | Recombinant IgG4 monovalent antibodies |
MX2009013004A (es) | 2007-06-01 | 2010-01-20 | Univ Maryland | Agentes de union al receptor de la region constante fc de inmunoglobulina. |
JP2010530222A (ja) * | 2007-06-06 | 2010-09-09 | べーリンガー インゲルハイム インターナショナル ゲーエムベーハー | ナトリウム利尿融合タンパク質 |
RU2010100638A (ru) * | 2007-06-12 | 2011-07-20 | УАЙТ ЭлЭлСи (US) | Композиции и способы лечения, направленные против cd20 |
EP2167130A2 (en) * | 2007-07-06 | 2010-03-31 | Trubion Pharmaceuticals, Inc. | Binding peptides having a c-terminally disposed specific binding domain |
WO2009052415A1 (en) * | 2007-10-17 | 2009-04-23 | The Regents Of The University Of California | Peptide for the induction of immune tolerance as treatment for systemic lupus erythematosus |
WO2009059278A1 (en) * | 2007-11-02 | 2009-05-07 | Centocor, Inc. | Semi-synthetic glp-1 peptide-fc fusion constructs, methods and uses |
SI2132228T1 (sl) * | 2008-04-11 | 2011-10-28 | Emergent Product Dev Seatle | CD37 imunoterapevtik in kombinacija z njegovim bifunkcionalnim kemoterapevtikom |
NZ590358A (en) | 2008-07-23 | 2012-04-27 | Hanmi Holdings Co Ltd | A polypeptide complex comprising non-peptidyl polymer having three functional ends |
RU2457856C2 (ru) * | 2008-08-05 | 2012-08-10 | Виктор Владимирович Чалов | Композиция, обладающая противовирусным и антимикробным действием, для перорального применения |
CN104829706A (zh) * | 2008-08-07 | 2015-08-12 | 益普生制药股份有限公司 | 糖依赖性胰岛素释放肽的类似物 |
EA020005B1 (ru) | 2008-08-07 | 2014-07-30 | Ипсен Фарма С.А.С. | Аналоги глюкозазависимого инсулинотропного полипептида |
BRPI0917580A2 (pt) * | 2008-08-07 | 2016-10-11 | Ipsen Pharma Sas | composto, composição farmacêutica, métodos para elicitar um efeito agonista e antagonista de um receptor de gip, para tratar condições ou doenças mediadas por ligação de receptor de gip, para tratar diabetes, para tratar distúrbios relacionados com diabete, para tratar ou previnir causas secundárias de diabete para tratar obesidade, e para estimular secreção de insulina, e, uso de um análogo de peptídeo |
EP2898900B1 (en) | 2008-09-19 | 2017-11-15 | Nektar Therapeutics | Polymer conjugates of ziconotide |
US8449872B2 (en) * | 2008-09-19 | 2013-05-28 | Nektar Therapeutics | Polymer conjugates of nesiritide peptides |
EP2344527A4 (en) * | 2008-10-31 | 2012-04-04 | Amgen Inc | MATERIALS AND METHODS FOR STEM CELL MOBILIZATION THROUGH A MULTIPLE PEGYLATED GRANULOCYTE COLONY STIMULATING FACTOR |
NZ604818A (en) | 2008-11-26 | 2014-07-25 | Amgen Inc | Variants of activin iib receptor polypeptides and uses thereof |
WO2010065578A2 (en) * | 2008-12-04 | 2010-06-10 | Leukosight Inc. | POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME |
US20100158893A1 (en) * | 2008-12-19 | 2010-06-24 | Baxter International Inc. | Systems and methods for obtaining immunoglobulin from blood |
AR075029A1 (es) * | 2009-01-19 | 2011-03-02 | Hanmi Pharm Ind Co Ltd | Metodo para producir una proteina o un peptido fisiologicamente activo usando un fragmento de inmunoglobulina |
US9238878B2 (en) | 2009-02-17 | 2016-01-19 | Redwood Bioscience, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
CN102333872B (zh) | 2009-02-25 | 2014-07-09 | 默沙东公司 | 在糖工程化的酵母巴斯德毕赤酵母中对半乳糖同化途径的代谢工程化 |
US20120142593A1 (en) * | 2009-03-24 | 2012-06-07 | Bayer Healthcare Llc | Factor VIII Variants and Methods of Use |
AU2010239861B2 (en) * | 2009-04-22 | 2013-07-11 | Alteogen, Inc | In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasing in vivo half-life using same |
CA2779577A1 (en) * | 2009-11-02 | 2011-05-05 | Therapeomic Ag | Stabilized protein formulations and use thereof |
WO2014121221A1 (en) | 2013-02-01 | 2014-08-07 | Santa Maria Biotherapeutics, Inc. | Administration of an anti-activin-a compound to a subject |
WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
EP2512460A4 (en) * | 2009-12-18 | 2015-01-21 | Exodos Life Sciences Ltd Partnership | METHOD AND COMPOSITIONS FOR STABLE LIQUID ACTIVE FORMULATIONS |
KR101340710B1 (ko) * | 2010-01-19 | 2013-12-12 | 한미사이언스 주식회사 | 지속형 과립구 콜로니 자극인자 결합체의 액상 제제 |
ES2700925T3 (es) * | 2010-01-19 | 2019-02-20 | Hanmi Science Co Ltd | Formulaciones líquidas para conjugado de eritropoyetina de acción prolongada |
WO2011093470A1 (ja) * | 2010-01-28 | 2011-08-04 | 協和発酵キリン株式会社 | Bone morphogenetic protein receptor 1B(BMPR1B)細胞外ドメイン又はその変異体を含む蛋白質を含有する骨疾患治療用医薬組成物 |
JP5976549B2 (ja) | 2010-02-24 | 2016-08-24 | メルク・シャープ・エンド・ドーム・コーポレイション | ピチア・パストリスにおいて産生される治療用糖タンパク質上のn−グリコシル化部位占拠を増加させるための方法 |
US9175067B2 (en) * | 2010-03-08 | 2015-11-03 | Ge Healthcare Bio-Sciences Ab | Immunoglobulin G Fc region binding polypeptide |
US9981017B2 (en) | 2010-04-02 | 2018-05-29 | Hanmi Science Co., Ltd. | Insulin conjugate using an immunoglobulin fragment |
AR080993A1 (es) * | 2010-04-02 | 2012-05-30 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina |
AR081755A1 (es) * | 2010-04-02 | 2012-10-17 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo |
AR081066A1 (es) * | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
KR20130118203A (ko) | 2010-04-30 | 2013-10-29 | 알렉시온 파마 인터내셔널 에스에이알엘 | 매트릭스 무기물화 장애의 처리방법, 조성물 및 키트 |
CN103124788B (zh) | 2010-05-21 | 2016-01-13 | 梅里麦克制药股份有限公司 | 双特异性融合蛋白 |
KR101330868B1 (ko) * | 2010-06-08 | 2013-11-18 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체 |
KR20120002129A (ko) * | 2010-06-30 | 2012-01-05 | 한미홀딩스 주식회사 | 면역글로불린 단편을 이용한 제7인자(Factor Ⅶa)약물 결합체 |
KR101337797B1 (ko) * | 2010-07-14 | 2013-12-06 | 한미사이언스 주식회사 | 지속형 인간 성장 호르몬 결합체 액상 제제 |
KR101382593B1 (ko) * | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
AR082404A1 (es) | 2010-07-28 | 2012-12-05 | Gliknik Inc | Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de inmunoglobulinas fc ordenadamente multimerizadas |
WO2012053828A2 (ko) * | 2010-10-20 | 2012-04-26 | 주식회사 한독약품 | 인간 인터루킨-1 수용체 길항제-하이브리드 Fc 융합단백질 |
US8883134B2 (en) | 2010-10-20 | 2014-11-11 | Handok Pharmaceuticals, Inc. | Human interleukin-1 receptor antagonist—hybrid Fc fusion protein |
KR101303388B1 (ko) * | 2010-10-26 | 2013-09-03 | 한미사이언스 주식회사 | 지속형 인터페론 알파 결합체의 액상 제제 |
EP2465536A1 (en) * | 2010-12-14 | 2012-06-20 | CSL Behring AG | CD89 activation in therapy |
JP5766296B2 (ja) | 2010-12-23 | 2015-08-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用 |
CA2823066A1 (en) | 2010-12-27 | 2012-07-05 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
RU2606016C2 (ru) | 2011-01-14 | 2017-01-10 | Редвуд Байосайнс, Инк. | Меченые альдегидом полипептиды иммуноглобулина и способы их применения |
CN102309765B (zh) * | 2011-02-28 | 2013-10-16 | 北京韩美药品有限公司 | 包含免疫球蛋白Fc片段作为载体的长效抗凝多肽及其制备方法 |
JP5977814B2 (ja) | 2011-04-08 | 2016-08-24 | アムジエン・インコーポレーテツド | 増殖分化因子15(gdf−15)を使用して代謝障害を治療または改善する方法 |
UA113626C2 (xx) * | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
CN102807619B (zh) * | 2011-06-03 | 2016-08-03 | 北京韩美药品有限公司 | 含有免疫球蛋白Fc片段和粒细胞-巨噬细胞集落刺激因子的复合物及其药物组合物 |
JP6014127B2 (ja) | 2011-06-10 | 2016-10-25 | ハンミ サイエンス カンパニー リミテッド | 新規なオキシントモジュリン誘導体及びそれを含む肥満治療用組成物 |
ES2710356T3 (es) * | 2011-06-17 | 2019-04-24 | Hanmi Science Co Ltd | Conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo |
EP3628327A1 (en) * | 2011-06-24 | 2020-04-01 | The Regents of the University of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
SG10201601621PA (en) * | 2011-06-28 | 2016-04-28 | Inhibrx Llc | Serpin fusion polypeptides and methods of use thereof |
MX356433B (es) * | 2011-06-28 | 2018-05-29 | Inhibrx Lp | Polipéptidos de fusión con domino de proteína ácida del suero, y métodos de uso de los mismos. |
MX358491B (es) * | 2011-09-05 | 2018-08-22 | Hanmi Science Co Ltd | Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa. |
TW201315742A (zh) * | 2011-09-26 | 2013-04-16 | Novartis Ag | 治療代謝病症之雙功能蛋白質 |
SG11201401205UA (en) * | 2011-10-06 | 2014-05-29 | Hanmi Science Co Ltd | Blood coagulation factor ? and ?a derivatives, conjugates and complexes comprising the same, and use thereof |
EP2784080B1 (en) * | 2011-10-31 | 2019-12-18 | Shimadzu Corporation | Peptide-hinge-free flexible antibody-like molecule |
KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
BR112014015003A2 (pt) | 2011-12-19 | 2019-09-24 | Amgen Inc | composição farmacêutica, método para tratar um cancer e método para reduzir o tamanho de uma massa tumoral |
CN103172745A (zh) * | 2011-12-21 | 2013-06-26 | 北京韩美药品有限公司 | 包含免疫球蛋白Fc片段的长效人内皮抑素 |
KR102041412B1 (ko) * | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Fc 단편 유도체 |
KR101895047B1 (ko) * | 2011-12-30 | 2018-09-06 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 |
EP3663314A1 (en) | 2012-01-09 | 2020-06-10 | The Scripps Research Institute | Humanized antibodies with ultralong cdr3s |
CN104520321A (zh) | 2012-01-09 | 2015-04-15 | 斯克利普斯研究所 | 超长互补决定区及其用途 |
CA2896951A1 (en) | 2012-01-10 | 2013-07-18 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
KR20140125803A (ko) | 2012-01-26 | 2014-10-29 | 암젠 인크 | 성장 분화 인자 15(gdf-15) 폴리펩타이드들 |
AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
KR102142261B1 (ko) | 2012-03-09 | 2020-08-11 | 체에스엘 베링 아게 | 분비형 면역글로불린을 포함하는 조성물 |
EP2636681A1 (en) | 2012-03-09 | 2013-09-11 | CSL Behring AG | Process for enriching IgA |
EP2636684A1 (en) | 2012-03-09 | 2013-09-11 | CSL Behring AG | Prevention of infection |
US10064951B2 (en) | 2012-03-30 | 2018-09-04 | Hanmi Science Co., Ltd. | Liquid formulation of highly concentrated long-acting human growth hormone conjugate |
CA2871468C (en) * | 2012-04-23 | 2021-09-21 | Nrl Pharma, Inc. | Lactoferrin fusion protein and method for preparation thereof |
US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
EP2859017B1 (en) | 2012-06-08 | 2019-02-20 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
ES2611788T3 (es) | 2012-06-26 | 2017-05-10 | Sutro Biopharma, Inc. | Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso |
EP2867253B1 (en) | 2012-06-27 | 2016-09-14 | F. Hoffmann-La Roche AG | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
JP6309002B2 (ja) * | 2012-06-27 | 2018-04-11 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 標的に特異的に結合する少なくとも1つの結合実体を含む抗体Fc領域結合体を作製するための方法およびその使用 |
US10441665B2 (en) | 2012-07-25 | 2019-10-15 | Hanmi Pharm. Co., Ltd. | Liquid formulation of long acting insulinotropic peptide conjugate |
AR094821A1 (es) * | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
AR091902A1 (es) | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
AR092862A1 (es) | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
KR20150058236A (ko) | 2012-08-20 | 2015-05-28 | 글리크닉 인코포레이티드 | 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자 |
SI2890402T1 (sl) | 2012-08-31 | 2019-07-31 | Sutro Biopharma, Inc. | Modificirane aminokisline vsebujoče acido skupino |
RU2646159C2 (ru) | 2012-09-14 | 2018-03-01 | Ф. Хоффманн-Ля Рош Аг | Способ получения и отбора молекул, включающих по меньшей мере две различные группировки, и их применение |
US9561275B2 (en) | 2012-09-14 | 2017-02-07 | The Johns Hopkins University | Compositions and methods for rendering tumor cells susceptible to CD8+ T cell-mediated killing |
TWI602583B (zh) | 2012-11-06 | 2017-10-21 | 韓美藥品股份有限公司 | 包含調酸素及免疫球蛋白片段之蛋白質接合物的液態製劑 |
KR101993393B1 (ko) * | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
CN105073781A (zh) | 2013-01-11 | 2015-11-18 | 加州生物医学研究所 | 牛融合抗体 |
CN103217489B (zh) * | 2013-01-15 | 2016-03-09 | 珠海市丽珠单抗生物技术有限公司 | 一种测定蛋白纯化工艺过程中样品的糖基化和末端修饰情况的方法 |
KR102073748B1 (ko) * | 2013-01-31 | 2020-02-05 | 한미약품 주식회사 | 재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법 |
US9394515B2 (en) | 2013-02-22 | 2016-07-19 | Zoetis Services Llc | Poultry performance |
ES2743612T3 (es) * | 2013-03-05 | 2020-02-20 | Hanmi Pharm Ind Co Ltd | Procedimiento de preparación mejorado para producción de alto rendimiento de un conjugado de polipéptido fisiológicamente activo |
TW201513880A (zh) | 2013-03-11 | 2015-04-16 | Novo Nordisk As | 生長激素化合物 |
US20140271641A1 (en) * | 2013-03-14 | 2014-09-18 | University Of Guelph | Thrombospondin-1 polypeptides and methods of using same |
US9587235B2 (en) | 2013-03-15 | 2017-03-07 | Atyr Pharma, Inc. | Histidyl-tRNA synthetase-Fc conjugates |
AU2014228938B2 (en) | 2013-03-15 | 2019-05-02 | Bioverativ Therapeutics Inc. | Factor IX polypeptide formulations |
KR101895634B1 (ko) * | 2013-05-31 | 2018-09-05 | 한미약품 주식회사 | 변이된 힌지 영역을 포함하는 IgG4 Fc 단편 |
EP3019522B1 (en) | 2013-07-10 | 2017-12-13 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
AR096890A1 (es) * | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn |
AR096891A1 (es) * | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
CN105814074B (zh) | 2013-07-18 | 2020-04-21 | 图鲁斯生物科学有限责任公司 | 具有超长互补决定区的人源化抗体 |
JP6509852B2 (ja) | 2013-07-31 | 2019-05-08 | アムジエン・インコーポレーテツド | 増殖分化因子15(gdf−15)の構築物 |
WO2015031673A2 (en) | 2013-08-28 | 2015-03-05 | Bioasis Technologies Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
PL3041513T3 (pl) | 2013-09-08 | 2021-01-25 | Kodiak Sciences Inc. | Obojnaczojonowe polimerowe koniugaty czynnika viii |
EP3043810B1 (en) | 2013-09-09 | 2019-10-23 | CanImGuide Therapeutics AB | Immune system modulators |
CN105848645A (zh) | 2013-09-27 | 2016-08-10 | 韩美药品株式会社 | 持续型人生长激素制剂 |
EP3052697A1 (en) * | 2013-09-30 | 2016-08-10 | 3M Innovative Properties Company | Fibers and wipes with epoxidized fatty ester disposed thereon, and methods |
WO2015070210A1 (en) | 2013-11-11 | 2015-05-14 | Wake Forest University Health Sciences | Epha3 and multi-valent targeting of tumors |
WO2015108398A1 (ko) | 2014-01-20 | 2015-07-23 | 한미약품 주식회사 | 지속형 인슐린 및 그 용도 |
WO2015112597A1 (en) * | 2014-01-21 | 2015-07-30 | Belmont Biosciences, Inc. | Variants of igg fc with limited amine groups that retain functional properties |
PL3127923T3 (pl) * | 2014-03-31 | 2022-01-31 | Hanmi Pharm. Co., Ltd. | Sposób poprawy rozpuszczalności białka i peptydu przez zastosowanie fragmentu fc immunoglobuliny |
ES2719584T3 (es) * | 2014-04-11 | 2019-07-11 | Medimmune Llc | Compuestos conjugados que comprenden anticuerpos modificados por ingeniería genética con cisteína |
US10308703B2 (en) * | 2014-04-28 | 2019-06-04 | The National Institute For Biotechnology I | Variants of DR3 and use thereof |
KR20150133576A (ko) * | 2014-05-20 | 2015-11-30 | 삼성전자주식회사 | 화학적 개질된 표적화 단백질 및 그의 이용 |
AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及glp-1/昇糖素雙重促效劑之治療糖尿病之組成物 |
JP6822849B2 (ja) | 2014-06-27 | 2021-01-27 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | 多重特異的NKp46結合タンパク質 |
US11208480B2 (en) * | 2014-06-27 | 2021-12-28 | Innate Pharma | Multispecific antigen binding proteins |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
RU2021106673A (ru) | 2014-07-24 | 2021-11-25 | Дженентек, Инк. | Способы конъюгации агента с тиольным компонентом в белке, который содержит по меньшей мере одну трисульфидную связь |
TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
KR102210104B1 (ko) * | 2014-10-17 | 2021-02-01 | 코디악 사이언시스 인코포레이티드 | 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트 |
MX2017007392A (es) | 2014-12-05 | 2019-01-24 | Alexion Pharma Inc | Tratamiento de convulsiones con fosfatasa alcalina recombinante. |
KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
PE20171154A1 (es) | 2014-12-30 | 2017-08-16 | Hanmi Pharm Ind Co Ltd | Derivados de glucagon con estabilidad mejorada |
US10603361B2 (en) | 2015-01-28 | 2020-03-31 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
DK3265117T3 (da) | 2015-03-06 | 2021-02-08 | Canimguide Therapeutics Ab | Immunsystemmodulatorer og præparater |
MA53883A (fr) * | 2015-04-06 | 2021-08-18 | Acceleron Pharma Inc | Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations |
DK3286206T3 (da) | 2015-04-22 | 2021-05-03 | Biogen Ma Inc | Hidtil ukendte hybride actriib-ligand-trap-proteiner til behandling af muskelsvindsygdomme |
CA2979973A1 (en) * | 2015-04-29 | 2016-11-03 | Mediolanum Farmaceutici S.P.A. | A soluble chimeric interleukin-10 receptor and therapeutic use thereof |
CN107743494B (zh) | 2015-06-02 | 2022-04-29 | 诺和诺德股份有限公司 | 具有极性重组延伸体的胰岛素 |
CN107835693B (zh) * | 2015-06-12 | 2021-11-02 | 联亚药业股份有限公司 | 免疫球蛋白融合蛋白及其用途 |
US11820807B2 (en) * | 2015-06-12 | 2023-11-21 | Ubi Pharma Inc | Immunoglobulin fusion proteins and uses thereof |
WO2016207278A1 (en) | 2015-06-23 | 2016-12-29 | Innate Pharma | Multispecific nk engager proteins |
ES2973017T3 (es) | 2015-06-30 | 2024-06-18 | Hanmi Pharmaceutical Co Ltd | Derivado del glucagón y una composición que comprende un conjugado de acción prolongada del mismo |
KR20170012145A (ko) | 2015-07-24 | 2017-02-02 | 한미약품 주식회사 | 생리활성폴리펩타이드 결합체의 제조방법 |
EP3337894A1 (en) | 2015-08-17 | 2018-06-27 | Alexion Pharmaceuticals, Inc. | Manufacturing of alkaline phosphatases |
UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
EA201890613A1 (ru) | 2015-09-21 | 2018-10-31 | Аптево Рисёрч Энд Девелопмент Ллс | Полипептиды, связывающие cd3 |
JP7222710B2 (ja) * | 2015-09-24 | 2023-02-15 | ハンミ ファーマシューティカル カンパニー リミテッド | 免疫グロブリン断片の特定位置を連結部位として用いたタンパク質結合体 |
TW201718629A (zh) * | 2015-09-25 | 2017-06-01 | 韓美藥品股份有限公司 | 包含多個生理多肽及免疫球蛋白Fc區之蛋白質接合物 |
WO2017058822A1 (en) | 2015-09-28 | 2017-04-06 | Alexion Pharmaceuticals, Inc. | Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia |
MA43348A (fr) | 2015-10-01 | 2018-08-08 | Novo Nordisk As | Conjugués de protéines |
CN116063567A (zh) * | 2015-10-01 | 2023-05-05 | 热生物制品有限公司 | 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法 |
US10040840B2 (en) * | 2015-10-02 | 2018-08-07 | Silver Creek Pharmaceuticals, Inc. | Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue |
US20170095577A1 (en) * | 2015-10-06 | 2017-04-06 | Washington University | Noninvasive imaging of focal atherosclerotic lesions using fluorescence molecular tomography |
JP2018533571A (ja) | 2015-10-30 | 2018-11-15 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 患者の頭蓋縫合早期癒合症を治療するための方法 |
EP3395366B1 (en) * | 2015-12-21 | 2023-11-22 | Hefei Lifeon Pharmaceutical Co., Ltd. | Drug design method, obtained drug and application thereof |
SG11201805420SA (en) | 2015-12-30 | 2018-07-30 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
KR20170079409A (ko) * | 2015-12-30 | 2017-07-10 | 한미약품 주식회사 | 지속형 인간 성장 호르몬 결합체의 신규 액상 제제 |
MX2018008027A (es) | 2015-12-31 | 2018-11-29 | Hanmi Pharm Ind Co Ltd | Activador triple que activa receptor de glucagon, glp-1 y gip. |
CN109069664B (zh) | 2016-01-27 | 2022-05-13 | 苏特罗生物制药公司 | 抗cd74抗体偶联物,包含抗cd74抗体偶联物的组合物以及抗cd74抗体偶联物的使用方法 |
AR107483A1 (es) * | 2016-01-29 | 2018-05-02 | Hanmi Pharm Ind Co Ltd | Conjugado de enzimas terapéuticas |
US11065306B2 (en) | 2016-03-08 | 2021-07-20 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
EP3436020A4 (en) | 2016-04-01 | 2019-12-25 | Alexion Pharmaceuticals, Inc. | METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS |
US11186832B2 (en) | 2016-04-01 | 2021-11-30 | Alexion Pharmaceuticals, Inc. | Treating muscle weakness with alkaline phosphatases |
WO2017189432A1 (en) | 2016-04-26 | 2017-11-02 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
JP7020403B2 (ja) | 2016-05-02 | 2022-02-16 | 味の素株式会社 | アジド基含有Fcタンパク質 |
CN106008722B (zh) * | 2016-05-13 | 2019-10-15 | 未名生物医药有限公司 | 一种重组β-hNGF-Fc融合蛋白、制备方法及用途 |
US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
EP3464347B1 (en) | 2016-06-07 | 2023-05-31 | Gliknik Inc. | Cysteine-optimized stradomers |
AU2017289014B2 (en) | 2016-06-29 | 2019-12-05 | Hanmi Pharm. Co., Ltd. | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof |
JP7018933B2 (ja) | 2016-08-18 | 2022-02-14 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 気管気管支軟化症の治療方法 |
JOP20190019A1 (ar) * | 2016-08-30 | 2019-02-12 | Genexine Inc | تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH) |
BR112019005637A2 (pt) | 2016-09-23 | 2019-07-30 | Hanmi Pharm Ind Co Ltd | análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso |
US20200078470A1 (en) * | 2016-12-05 | 2020-03-12 | Hanmi Pharm. Co., Ltd. | Conjugate with attenuated immune response |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
BR112019009484A2 (pt) | 2016-12-09 | 2019-07-30 | Gliknik Inc | otimização de fabricação de gl-2045, um stradomer multimerizador |
CN110545849A (zh) * | 2017-02-03 | 2019-12-06 | 韩美药品株式会社 | 具有增加的持续性的生理活性物质的缀合物及其应用 |
MX2019009812A (es) | 2017-02-27 | 2019-10-14 | Shattuck Labs Inc | Proteinas quimericas basadas en tigit y light. |
AU2018223822A1 (en) | 2017-02-27 | 2019-07-11 | Shattuck Labs, Inc. | CSF1R-based chimeric proteins |
US11752216B2 (en) | 2017-03-23 | 2023-09-12 | Hanmi Pharm. Co., Ltd. | Insulin analog complex with reduced affinity for insulin receptor and use thereof |
EP3600383A4 (en) | 2017-03-31 | 2020-10-28 | Alexion Pharmaceuticals, Inc. | METHODS FOR TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS |
MA49339A (fr) * | 2017-04-05 | 2020-02-12 | Novo Nordisk As | Conjugués insuline-fc à extension oligomère |
AU2018256435A1 (en) | 2017-04-20 | 2019-11-07 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
US20200131225A1 (en) * | 2017-04-20 | 2020-04-30 | Novo Nordisk A/S | Methods of purification of albumin fusion proteins |
CN109206522B (zh) * | 2017-07-07 | 2021-11-09 | 北京三有利和泽生物科技有限公司 | 一种长效抗凝血融合蛋白及其应用 |
JP6566324B2 (ja) * | 2017-09-29 | 2019-08-28 | サイデン化学株式会社 | 粘着シート |
US20200283492A1 (en) * | 2017-09-29 | 2020-09-10 | Hanmi Pharm Co., Ltd. | Long acting protein complex having an enhanced efficiency |
PE20210347A1 (es) | 2017-10-02 | 2021-02-25 | Denali Therapeutics Inc | Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas |
KR102167827B1 (ko) * | 2017-12-20 | 2020-10-20 | 주식회사 알테오젠 | 신규한 성장 호르몬 수용체 길항제 및 이의 융합 단백질 |
CN108218998A (zh) * | 2017-12-31 | 2018-06-29 | 武汉班科生物技术股份有限公司 | 一种突变型人源IgG的Fc片段及其制备方法与应用 |
KR101974305B1 (ko) * | 2018-02-14 | 2019-04-30 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
SG11202008242XA (en) | 2018-03-02 | 2020-09-29 | Kodiak Sciences Inc | Il-6 antibodies and fusion constructs and conjugates thereof |
WO2019190990A1 (en) * | 2018-03-26 | 2019-10-03 | Regeneron Pharmaceuticals, Inc. | Humanized rodents for testing therapeutic agents |
KR102209108B1 (ko) | 2018-03-27 | 2021-01-28 | 국립암센터 | Oct4 기능 저해용 펩티드를 포함하는 줄기세포성 억제용 조성물 |
EP3773684A1 (en) | 2018-03-30 | 2021-02-17 | Alexion Pharmaceuticals, Inc. | Manufacturing of glycoproteins |
MA52205A (fr) | 2018-04-09 | 2021-02-17 | Amgen Inc | Protéines de fusion du facteur de différenciation de croissance 15 |
US10780121B2 (en) | 2018-08-29 | 2020-09-22 | Shattuck Labs, Inc. | FLT3L-based chimeric proteins |
KR20200124176A (ko) * | 2019-04-23 | 2020-11-02 | 주식회사 엘지화학 | 면역글로불린의 Fc 영역 및 GDF15를 포함하는 융합 폴리펩타이드 |
US11267858B2 (en) * | 2019-05-31 | 2022-03-08 | Spectrum Pharmaceuticals, Inc. | Methods of treatment using G-CSF protein complex |
CN112142850A (zh) * | 2019-06-27 | 2020-12-29 | 深圳市卫光生物制品股份有限公司 | 人神经生长因子-乳铁蛋白重组蛋白及用途 |
CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
CN110669134A (zh) * | 2019-10-15 | 2020-01-10 | 广东菲鹏生物有限公司 | IgM-FC片段、IgM-FC抗体及制备方法和应用 |
CN114867739A (zh) * | 2019-12-11 | 2022-08-05 | 株式会社Lg化学 | 包含gdf15和能够进行o-糖基化的多肽区的融合多肽 |
CN111153996B (zh) * | 2020-01-10 | 2021-12-14 | 苏州睿瀛生物技术有限公司 | G蛋白偶联受体的抗体及其制备方法和g蛋白偶联受体试剂盒 |
CN111505291B (zh) * | 2020-04-14 | 2023-04-25 | 山东省千佛山医院 | 一种排除巨酶分子对血清酶浓度检测带来干扰的方法 |
WO2021235915A1 (ko) | 2020-05-22 | 2021-11-25 | 한미약품 주식회사 | 액상 제제 |
CN112098639B (zh) * | 2020-09-21 | 2024-01-02 | 天津医科大学 | 以氧化石墨烯为载体的二抗的合成及应用 |
KR20230145120A (ko) | 2021-02-12 | 2023-10-17 | 알렉시온 파마슈티칼스, 인코포레이티드 | 알칼리성 포스파타제 폴리펩타이드 및 이의 사용 방법 |
CA3242378A1 (en) * | 2022-01-28 | 2023-08-03 | Roeland VANHAUWAERT | Anti-musk antibodies for use in treating neuromuscular disorders |
AU2023228691A1 (en) * | 2022-03-03 | 2024-09-19 | The Trustees Of The University Of Pennsylvania | Viral vectors encoding parathyroid hormone fusions and uses thereof in treating hypoparathyroidism |
CN114588315A (zh) * | 2022-03-14 | 2022-06-07 | 东莞市人民医院 | 抗炎蛋白涂层的制备方法、生物工程功能材料及其应用 |
WO2024123675A2 (en) * | 2022-12-05 | 2024-06-13 | Alexion Pharmaceuticals, Inc. | Taci-fc fusion proteins for multifunctional inhibition of baff, april, and neonatal fc receptor |
WO2024148240A1 (en) | 2023-01-06 | 2024-07-11 | Lassen Therapeutics 1, Inc. | ANTI-IL-11Rα ANTIBODIES FOR TREATING THYROID EYE DISEASE |
WO2024148241A1 (en) | 2023-01-06 | 2024-07-11 | Lassen Therapeutics 1, Inc. | Anti-il-18bp antibodies |
WO2024148243A1 (en) | 2023-01-06 | 2024-07-11 | Lassen Therapeutics 1, Inc. | Anti-il-18bp antibodies |
Family Cites Families (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
GB8504099D0 (en) * | 1985-02-18 | 1985-03-20 | Wellcome Found | Physiologically active substances |
JPS62153300A (ja) * | 1985-12-26 | 1987-07-08 | Teijin Ltd | ヒト免疫グロブリンGFc領域蛋白質およびその製造方法 |
JPH0728746B2 (ja) | 1986-02-28 | 1995-04-05 | 理化学研究所 | 新規プラスミド、微生物細胞及びヒト免疫グロブリンG Fc領域蛋白質の製造法 |
US5643758A (en) * | 1987-03-10 | 1997-07-01 | New England Biolabs, Inc. | Production and purification of a protein fused to a binding protein |
JPS63245691A (ja) | 1987-03-31 | 1988-10-12 | Teijin Ltd | ヒト免疫グロブリンGFc領域蛋白質およびその製造方法 |
JPS63290899A (ja) | 1987-05-22 | 1988-11-28 | Takeda Chem Ind Ltd | ヒトIgEFc蛋白質のフラグメントおよびその製造法 |
US6710169B2 (en) * | 1987-10-02 | 2004-03-23 | Genentech, Inc. | Adheson variants |
DE3889546T2 (de) | 1987-12-21 | 1994-09-08 | Univ Toledo | Transformation von keimenden pflanzensamen mit hilfe von agrobacterium. |
US6018026A (en) | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
US6004781A (en) | 1988-01-22 | 1999-12-21 | The General Hospital Corporation | Nucleic acid encoding Ig-CD4 fusion proteins |
US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
GB8824869D0 (en) | 1988-10-24 | 1988-11-30 | Stevenson G T | Synthetic antibody |
US6406697B1 (en) | 1989-02-23 | 2002-06-18 | Genentech, Inc. | Hybrid immunoglobulins |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US6307025B1 (en) | 1989-04-28 | 2001-10-23 | Biogen, Inc. | VCAM fusion proteins and DNA coding therefor |
FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
US5605690A (en) * | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
US6541610B1 (en) | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
GB9009106D0 (en) | 1990-04-23 | 1990-06-20 | 3I Res Expl Ltd | Processes and intermediates for synthetic antibody derivatives |
US5349053A (en) * | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
ATE169030T1 (de) | 1990-06-28 | 1998-08-15 | Hoechst Ag | Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung |
US7253264B1 (en) * | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
US5650150A (en) | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
US5191066A (en) | 1990-12-07 | 1993-03-02 | Abbott Laboratories | Site-specific conjugation of immunoglobulins and detectable labels |
AU660662B2 (en) | 1991-02-08 | 1995-07-06 | Progenics Pharmaceuticals, Inc. | CD4-gamma2 and CD4-IgG2 chimeras |
ES2199935T3 (es) | 1991-03-15 | 2004-03-01 | Amgen Inc. | Pegilacion de polipeptidos. |
EP0537166B1 (fr) * | 1991-04-17 | 1999-07-07 | Medisup International N.V. | Polypeptides hydrosolubles ayant une haute affinite pour les interferons alpha et beta |
EP0533006A1 (en) | 1991-09-18 | 1993-03-24 | F.Hoffmann-La Roche & Co. Aktiengesellschaft | Chimaeric interleukin 5-receptor/immunoglobulin polypeptides |
US20020037558A1 (en) | 1991-10-23 | 2002-03-28 | Kin-Ming Lo | E.coli produced immunoglobulin constructs |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
JPH0640945A (ja) | 1992-07-23 | 1994-02-15 | Kureha Chem Ind Co Ltd | Fcフラグメント結合抗腫瘍剤 |
WO1994003191A1 (en) * | 1992-08-07 | 1994-02-17 | Progenics Pharmaceuticals, Inc. | NON-PEPTIDYL MOIETY-CONJUGATED CD4-GAMMA2 AND CD4-IgG2 IMMUNOCONJUGATES, AND USES THEREOF |
IT1263831B (it) | 1993-01-29 | 1996-09-04 | Paolo Chiesi | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina |
US6482919B2 (en) | 1993-02-01 | 2002-11-19 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US5470952A (en) | 1993-10-20 | 1995-11-28 | Regeneron Pharmaceuticals, Inc. | CNTF and IL-6 antagonists |
US5738846A (en) | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
US6410008B1 (en) * | 1994-12-12 | 2002-06-25 | Beth Israel Hospital Association | Chimeric IL-10 proteins and uses thereof |
US6030613A (en) * | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US5977310A (en) * | 1995-03-10 | 1999-11-02 | Toshikazu Nakamura And Sumitomo Pharmaceuticals Co., Ltd. | Peg-modified HGF |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
GB9511935D0 (en) | 1995-06-13 | 1995-08-09 | Smithkline Beecham Plc | Novel compound |
WO1997010850A1 (en) * | 1995-09-21 | 1997-03-27 | Andaris Limited | Transcytosis vehicles and enhancers for drug delivery |
US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
US6620413B1 (en) * | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
KR19980038061A (ko) | 1996-11-23 | 1998-08-05 | 유우준 | 음식물 쓰레기 수분분리 처리장치 |
US7122636B1 (en) * | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
MY118835A (en) * | 1997-04-18 | 2005-01-31 | Ipsen Pharma Biotech | Sustained release compositions and the process for their preparation |
US5990237A (en) * | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
US6165476A (en) | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
WO1999002709A1 (en) | 1997-07-10 | 1999-01-21 | Beth Israel Deaconess Medical Center | Recombinant erythropoietin / immunoglobulin fusion proteins |
US6451986B1 (en) * | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
US6703381B1 (en) * | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
KR100316347B1 (ko) * | 1998-09-15 | 2002-08-27 | 한미약품(주) | 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법 |
CA2343094A1 (en) * | 1998-10-16 | 2000-04-27 | Biogen, Inc. | Interferon-beta fusion proteins and uses |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
BR0007414A (pt) | 1999-01-07 | 2001-10-16 | Lexigen Pharm Corp | Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
WO2000046380A2 (en) | 1999-02-08 | 2000-08-10 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
US20040266673A1 (en) * | 2002-07-31 | 2004-12-30 | Peter Bakis | Long lasting natriuretic peptide derivatives |
BR0010725A (pt) * | 1999-05-19 | 2002-02-19 | Lexigen Pharm Corp | Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc |
US6833349B2 (en) * | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
JP2003505020A (ja) * | 1999-07-02 | 2003-02-12 | ジェネンテック・インコーポレーテッド | ペプチドリガンドドメイン及び多量体化ドメインを含む融合ペプチド |
PE20010288A1 (es) | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
AU782496B2 (en) | 1999-07-13 | 2005-08-04 | Bolder Biotechnology, Inc. | Immunoglobulin fusion proteins |
KR100360594B1 (ko) * | 2000-01-19 | 2002-11-13 | 한미약품공업 주식회사 | 인간 인터페론 알파의 발현 분비벡터 및 이를 이용한인터페론 알파의 생산 방법 |
ATE319737T1 (de) | 2000-04-21 | 2006-03-15 | Amgen Inc | Peptidderivate des apolipoproteins-a1/aii |
US6756480B2 (en) * | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
US20020168367A1 (en) * | 2000-04-28 | 2002-11-14 | Planet Biotechnology Incorporated | Novel immunoadhesins for treating and preventing viral and bacterial diseases |
US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
DE10021731B4 (de) | 2000-05-04 | 2005-12-08 | Aventis Pharma Deutschland Gmbh | Cyclipostine, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung derselben |
US6417237B1 (en) | 2000-06-08 | 2002-07-09 | The Board Of Trustees Of The University Of Illinois | Macromolecular drug complexes and compositions containing the same |
MXPA03005036A (es) | 2000-12-07 | 2003-09-05 | Lilly Co Eli | Proteinas de fusion glp-1. |
US6979556B2 (en) | 2000-12-14 | 2005-12-27 | Genentech, Inc. | Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes |
KR100841486B1 (ko) | 2000-12-14 | 2008-06-25 | 제넨테크, 인크. | 박테리아 숙주 균주 |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
CN1630720A (zh) | 2001-01-18 | 2005-06-22 | 默克专利有限公司 | 具有葡糖脑苷脂酶活性的双功能融合蛋白 |
KR20040074587A (ko) * | 2001-02-19 | 2004-08-25 | 메르크 파텐트 게엠베하 | 감소된 면역원성을 갖는 인공 단백질 |
KR100566911B1 (ko) | 2001-06-25 | 2006-04-03 | 주식회사 삼양사 | 약물 전달체용 음이온기-함유 양친성 블록 공중합체 및 그의 양이온성 약물과의 복합체 |
EP1411983A4 (en) | 2001-06-26 | 2006-06-21 | Imclone Systems Inc | BISPECIFIC ANTIBODIES BINDING TO VEGF RECEPTORS |
EP1411987A2 (en) * | 2001-07-31 | 2004-04-28 | Immunomedics, Inc. | Targeted polymeric delivery systems |
US6900292B2 (en) * | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
US6797493B2 (en) * | 2001-10-01 | 2004-09-28 | Lee-Hwei K. Sun | Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities |
US7125843B2 (en) * | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
KR100811138B1 (ko) | 2001-11-13 | 2008-03-07 | 오리온피디피주식회사 | 저온소성세라믹기판을 이용한 다층회로기판의 제조방법과 이에 의해 제조된 다층회로기판 |
AU2002357072A1 (en) * | 2001-12-07 | 2003-06-23 | Centocor, Inc. | Pseudo-antibody constructs |
WO2003074679A2 (en) * | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
AU2003210806A1 (en) | 2002-03-05 | 2003-09-22 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
CN101143221A (zh) * | 2002-03-15 | 2008-03-19 | 布赖汉姆妇女医院 | 适合治疗剂全身性递送的中央气道给药 |
US20030191056A1 (en) * | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
WO2004024889A2 (en) * | 2002-09-16 | 2004-03-25 | Elusys Therapeutics, Inc. | Production of bispecific molecules using polyethylene glycol linkers |
CA2499300A1 (en) * | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
RS52815B (sr) | 2002-12-20 | 2013-10-31 | Amgen Inc. | Vezivna sredstva koja inhibiraju miostatin |
WO2004064731A2 (en) | 2003-01-14 | 2004-08-05 | University Of Washington | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymlplhoid tissues |
US20050176108A1 (en) * | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
KR20040083268A (ko) | 2003-03-21 | 2004-10-01 | 한미약품 주식회사 | 안정성이 증가된 인간 과립구 콜로니 자극인자 융합체 및이의 제조방법 |
PL1624891T5 (pl) | 2003-05-06 | 2014-02-28 | Bioverativ Therapeutics Inc | Białka chimeryczne o strukturze czynnik krzepliwości krwi-fc do leczenia hemofilii |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US20050281829A1 (en) | 2003-05-06 | 2005-12-22 | Hehir Cristina A T | Fc chimeric proteins with anti-HIV drugs |
WO2005007809A2 (en) * | 2003-05-30 | 2005-01-27 | Alexion Pharmaceuticals, Inc. | Antibodies and fusion proteins that include engineered constant regions |
EP1682582B1 (en) * | 2003-11-13 | 2011-08-31 | Hanmi Holdings Co., Ltd | Method for the mass production of immunoglobulin constant region |
US7601516B2 (en) | 2004-01-28 | 2009-10-13 | Syntomix Pharmaceuticals, Inc. | Heterodimeric follicle stimulating hormone-Fc (FSH-Fc) fusion proteins for the treatment of infertility |
AU2005289594B2 (en) * | 2004-09-27 | 2012-02-02 | Centocor, Inc. | Srage mimetibody, compositions, methods and uses |
KR100594607B1 (ko) * | 2004-11-03 | 2006-06-30 | 재단법인서울대학교산학협력재단 | 신규한 경구투여용 재조합 인간 성장호르몬 분비미생물제제 및 그 제조방법 |
KR100754667B1 (ko) * | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물 |
JP2010106019A (ja) | 2008-10-02 | 2010-05-13 | Kanazawa Univ | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および/または症状軽減剤 |
AR081066A1 (es) * | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
AR080993A1 (es) * | 2010-04-02 | 2012-05-30 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina |
AR081755A1 (es) * | 2010-04-02 | 2012-10-17 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo |
KR20120002129A (ko) * | 2010-06-30 | 2012-01-05 | 한미홀딩스 주식회사 | 면역글로불린 단편을 이용한 제7인자(Factor Ⅶa)약물 결합체 |
-
2004
- 2004-11-13 EP EP04800090A patent/EP1682582B1/en active Active
- 2004-11-13 PT PT100091297T patent/PT2256134E/pt unknown
- 2004-11-13 MX MXPA05007211A patent/MXPA05007211A/es active IP Right Grant
- 2004-11-13 PT PT100063262T patent/PT2239273E/pt unknown
- 2004-11-13 MX MXPA05007210A patent/MXPA05007210A/es active IP Right Grant
- 2004-11-13 ES ES10006326.2T patent/ES2438098T3/es active Active
- 2004-11-13 RU RU2005120240/13A patent/RU2356909C2/ru active
- 2004-11-13 WO PCT/KR2004/002942 patent/WO2005047334A1/en active Application Filing
- 2004-11-13 CA CA2512933A patent/CA2512933C/en not_active Expired - Fee Related
- 2004-11-13 ES ES04800092T patent/ES2426169T3/es active Active
- 2004-11-13 KR KR1020040092781A patent/KR100775343B1/ko active Protection Beyond IP Right Term
- 2004-11-13 ES ES04800091T patent/ES2378167T3/es active Active
- 2004-11-13 BR BR0406606-5A patent/BRPI0406606A/pt not_active Application Discontinuation
- 2004-11-13 US US10/535,312 patent/US8029789B2/en active Active
- 2004-11-13 ES ES04800089T patent/ES2383300T3/es active Active
- 2004-11-13 CN CN201210190634.9A patent/CN103212084B/zh active Active
- 2004-11-13 KR KR1020040092780A patent/KR20050047030A/ko not_active Application Discontinuation
- 2004-11-13 AU AU2004282984A patent/AU2004282984B2/en active Active
- 2004-11-13 US US10/535,341 patent/US8846874B2/en active Active
- 2004-11-13 US US10/535,232 patent/US7737260B2/en active Active
- 2004-11-13 ES ES10009129.7T patent/ES2454666T3/es active Active
- 2004-11-13 ES ES04800090T patent/ES2372495T3/es active Active
- 2004-11-13 DK DK10009129.7T patent/DK2256134T3/da active
- 2004-11-13 US US10/535,231 patent/US7736653B2/en active Active
- 2004-11-13 EP EP04800091A patent/EP1682583B1/en active Active
- 2004-11-13 KR KR1020040092782A patent/KR100725315B1/ko active Protection Beyond IP Right Term
- 2004-11-13 PT PT04800091T patent/PT1682583E/pt unknown
- 2004-11-13 EP EP10006326.2A patent/EP2239273B1/en active Active
- 2004-11-13 WO PCT/KR2004/002944 patent/WO2005047336A1/en active Application Filing
- 2004-11-13 PL PL10009129T patent/PL2256134T3/pl unknown
- 2004-11-13 RU RU2005120239/13A patent/RU2352583C2/ru active
- 2004-11-13 DK DK04800091.3T patent/DK1682583T3/da active
- 2004-11-13 AT AT04800090T patent/ATE522548T1/de not_active IP Right Cessation
- 2004-11-13 JP JP2006539396A patent/JP2007531513A/ja active Pending
- 2004-11-13 EP EP10009129.7A patent/EP2256134B1/en active Active
- 2004-11-13 EP EP04800092.1A patent/EP1682584B1/en active Active
- 2004-11-13 CN CN2004800017702A patent/CN1723219B/zh active Active
- 2004-11-13 WO PCT/KR2004/002943 patent/WO2005047335A1/en active Application Filing
- 2004-11-13 JP JP2006539398A patent/JP4870569B2/ja active Active
- 2004-11-13 BR BRPI0406605A patent/BRPI0406605B8/pt active IP Right Grant
- 2004-11-13 CA CA2512657A patent/CA2512657C/en active Active
- 2004-11-13 CN CNA2004800017755A patent/CN1723220A/zh active Pending
- 2004-11-13 PL PL10006326T patent/PL2239273T3/pl unknown
- 2004-11-13 AT AT04800089T patent/ATE555133T1/de active
- 2004-11-13 DK DK10006326.2T patent/DK2239273T3/da active
- 2004-11-13 EP EP04800089A patent/EP1682581B1/en active Active
- 2004-11-13 AU AU2004282985A patent/AU2004282985B8/en active Active
- 2004-11-13 KR KR1020040092783A patent/KR100725314B1/ko active IP Right Grant
- 2004-11-13 JP JP2006539399A patent/JP5216216B2/ja active Active
- 2004-11-13 JP JP2006539397A patent/JP4762904B2/ja active Active
- 2004-11-13 CN CN201810616347.7A patent/CN108743967B/zh active Active
- 2004-11-13 AT AT04800091T patent/ATE540980T1/de active
- 2004-11-13 WO PCT/KR2004/002945 patent/WO2005047337A1/en active Application Filing
-
2006
- 2006-04-24 KR KR1020060036697A patent/KR20060054252A/ko active Search and Examination
-
2007
- 2007-05-03 US US11/744,162 patent/US20080085862A1/en not_active Abandoned
- 2007-05-10 US US11/747,153 patent/US20080124347A1/en not_active Abandoned
-
2010
- 2010-04-09 US US12/757,635 patent/US20100255014A1/en not_active Abandoned
-
2011
- 2011-04-13 HK HK11103711.9A patent/HK1149570A1/xx unknown
- 2011-04-15 US US13/087,593 patent/US8822650B2/en active Active
- 2011-05-06 HK HK11104515.5A patent/HK1150612A1/xx unknown
- 2011-09-15 JP JP2011202199A patent/JP5425150B2/ja not_active Expired - Fee Related
- 2011-09-26 JP JP2011209594A patent/JP2011256211A/ja not_active Abandoned
-
2012
- 2012-07-26 JP JP2012166208A patent/JP2012224635A/ja not_active Withdrawn
-
2013
- 2013-03-12 US US13/796,135 patent/US10071166B2/en active Active
-
2014
- 2014-07-09 US US14/327,064 patent/US10272159B2/en active Active
- 2014-07-09 US US14/327,120 patent/US9750820B2/en active Active
-
2018
- 2018-07-20 US US16/041,263 patent/US20180326083A1/en active Pending
-
2019
- 2019-03-12 US US16/351,338 patent/US11058776B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1682583T3 (da) | Proteinkompleksdannelse under anvendelse af immunoglobulinfragment samt fremgangsmåde til fremstilling deraf | |
NO2017027I1 (no) | efmoroctocog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet. | |
WO2003068924A3 (en) | Fusion proteins of humanized g250 specific antibodies and uses thereof | |
DE60334364D1 (de) | Behandlungsverfahren unter verwendung von anti-cd22-antikörpern | |
WO2007048037A3 (en) | METHODS FOR GENERATING MONOVALENT IgG | |
MY162525A (en) | Process for concentration of antibodies and therapeutic products thereof | |
EA200700917A1 (ru) | Способ рефолдинга рекомбинантных антител | |
SG153874A1 (en) | Neutralizing epitope-based growth enhancing vaccine | |
IL174794A0 (en) | Bispecific antibody substituting for functional proteins | |
WO2004110472A3 (en) | Fusion proteins | |
WO2003074004A3 (en) | Method of producing antigens | |
WO2003068977A3 (de) | Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden | |
DE60227367D1 (de) | Modifizierter granulozyten stimulierender factor (g-csf) mit verringerter immunogenität | |
TH78296B (th) | แอนติบอดีต่อ opgl |